SAT-094 Evaluation of IGF-1 as a Biomarker to Inform Phase 3 Clinical Trial Design and Dose Selection in Patients Born Small for Gestational Age Who Fail to Demonstrate Catch-Up Growth by Age 2–4 Years

Insulin-like growth factor-1 (IGF-1) is a key hormone in mediating the physiological response to endogenous and exogenous growth hormone (GH). Current clinical guidelines suggest use of IGF-1 for dose titration in adults with GH deficiency and for safety monitoring in adults and pediatric patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tao, Penzenstadler, Justin, Cicali, Brain, Zemskova, Marina S, Vaidyanathan, Jayabharathi, Sahajwalla, Chandrahas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207440/
http://dx.doi.org/10.1210/jendso/bvaa046.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207440/
http://dx.doi.org/10.1210/jendso/bvaa046.003

Ejemplares similares